Pliant Therapeutics Reports Promising Interim Results for PLN-101095 in Refractory Solid Tumors
Pliant Therapeutics announced promising interim results from its Phase 1 trial of PLN-101095 for refractory solid tumors. The trial showed one complete response and three partial responses in high dose cohorts, with a median treatment duration of 15 months. A Phase 1b expansion trial is planned for 2026, and final data will be presented at a scientific conference. The news was generated by Public Technologies using AI and is for informational purposes only.
Pliant Therapeutics Inc. has announced interim data from its Phase 1 dose escalation clinical trial evaluating PLN-101095, an oral, small molecule dual selective inhibitor of αvβ8 and αvβ1, in combination with pembrolizumab for patients with immune checkpoint inhibitor-refractory advanced or metastatic solid tumors. The interim results include one complete response and three partial responses among heavily pretreated patients in high dose cohorts, with a median treatment duration of 15 months. The company plans to initiate a Phase 1b expansion trial in 2026. Final data from this trial will be presented at an upcoming scientific conference. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596725-en) on December 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
